# Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.

> **NCT00320801** · PHASE3 · TERMINATED · sponsor: **Purdue Pharma LP** · enrollment: 188 (actual)

## Conditions studied

- Osteoarthritis

## Interventions

- **DRUG:** Buprenorphine transdermal patch
- **DRUG:** Buprenorphine transdermal patch

## Key facts

- **NCT ID:** NCT00320801
- **Lead sponsor:** Purdue Pharma LP
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-01
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 188 (ACTUAL)
- **Why stopped:** This study was terminated early due to administrative reasons.
- **Last updated:** 2012-09-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00320801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00320801, "Buprenorphine Transdermal Patches (BTDS) in Subjects With Osteoarthritis Pain. Includes a 52-week Extension Phase.". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00320801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*